JIUZHITANG CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.58 CNY | +2.02% |
|
+6.65% | -34.98% |
| May. 20 | Jiuzhitang Co., Ltd. Approves Final Cash Dividend for the Year 2023 | CI |
| May. 08 | Jiuzhitang Co., Ltd.(XSEC:000989) dropped from S&P Global BMI Index | CI |
| Sales 2022 | 3.03B 417M | Sales 2023 | 2.96B 407M | Capitalization | 8.66B 1.19B |
|---|---|---|---|---|---|
| Net income 2022 | 359M 49.36M | Net income 2023 | 297M 40.84M | EV / Sales 2022 | 2.16 x |
| Net cash position 2022 | 1B 138M | Net cash position 2023 | 774M 106M | EV / Sales 2023 | 2.66 x |
| P/E ratio 2022 |
21
x | P/E ratio 2023 |
29.1
x | Employees | 3,519 |
| Yield 2022 |
4.54% | Yield 2023 |
3.95% | Free-Float | 45.44% |
More Fundamentals
* Assessed data
More news
| 1 day | +2.02% | ||
| 1 week | +6.65% | ||
| Current month | +3.13% | ||
| 1 month | -1.35% | ||
| 3 months | -25.98% | ||
| 6 months | -36.12% | ||
| Current year | -34.98% |
1 week
6.28
6.68
1 month
6.107.12
Current year
6.1010.54
1 year
6.1013.25
3 years
6.1015.50
5 years
6.1015.50
10 years
6.1029.51
| Managers | Title | Age | Since |
|---|---|---|---|
Xiang Ping Xu
CEO | Chief Executive Officer | 53 | 14-11-19 |
Wei Xiang Sun
DFI | Director of Finance/CFO | 58 | 16-01-15 |
Yan Song Gao
BRD | Director/Board Member | 42 | 20-02-26 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Xiang Ping Xu
CEO | Chief Executive Officer | 53 | 14-11-19 |
Zhen Guo Li
CHM | Chairman | 64 | 16-01-15 |
Chun Feng Liu
BRD | Director/Board Member | 61 | 20-02-26 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 32 M€ | +4.45% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-02 | 6.58 | +2.02% | 6,218,264 |
| 24-07-01 | 6.45 | +1.10% | 4,379,403 |
| 24-06-28 | 6.38 | +0.79% | 6,334,250 |
| 24-06-27 | 6.33 | 0.00% | 4,645,200 |
| 24-06-26 | 6.33 | +2.59% | 5,629,727 |
End-of-day quote Shenzhen S.E., July 01, 2024
More quotes
JIUZHITANG CO.,Ltd. is a China-based company principally engaged in the research, development, production and distribution of Chinese patent drugs. The Company provides products through three categories, which include over the counter (OTC) drugs, prescription drugs and comprehensive health series. The Companyâs main products include Liuwei Dihuang pills, Xiaoyao pills, Shuxuetong injection, compound Jiangzhi tablets and E-Jiao series health products, among others. The Company distributes its products in domestic market.
Sector
Pharmaceuticals
Calendar
2024-08-29
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -34.98% | 760M | |
| +27.29% | 5.63B | |
| -33.07% | 3.57B | |
| -3.24% | 3.08B | |
| -24.56% | 2.65B | |
| -10.17% | 2.29B | |
| +46.81% | 1.99B | |
| +48.03% | 1.54B | |
| -11.69% | 1.45B | |
| +43.81% | 1.39B |
- Stock Market
- Equities
- 000989 Stock
